A review of 6 placebo-managed clinical trials with 1,134 overall participants concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) have been associated with a greater ordinary advancement to the Ashworth scale for spasticity in several sclerosis sufferers as opposed with placebo, Th